Dual scans to find head and neck cancer spread
Treatments studied
Part of Cancer clinical trials.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 19 years or older
- Have biopsy-confirmed squamous cell carcinoma of the head and neck
- Be scheduled for planned neck surgery (neck dissection) for either no known nodes (cN0) or known/suspected nodes
- Have blood test numbers that are high enough: hemoglobin 9+; white blood cells over 3000; platelets 100,000+
- Have kidney function, liver health, and other blood chemistry within allowed limits, including enough magnesium and potassium
- Be able to sign informed consent and understand the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a labelling of panitumumab with iodine (111In) to see how well it can identify lymph nodes in head and neck cancer before surgery. The goal is to improve lymph node staging (which can help guide treatment), with the main focus on safety and early performance.
This Phase 1 study tests a new way to use a scan (PET/CT) with a drug called panitumumab to help spot where head and neck squamous cell cancer has spread. It may help doctors better target treatment by finding metastases earlier or more clearly.
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
This early-phase study compares a special imaging marker with a standard PET scan to help identify head and neck squamous cell carcinoma before surgery. It may help doctors see where cancer is (especially if lymph nodes look negative) so surgery planning can be more accurate.
This study tests a special PET/CT scan that may help doctors see the cancer more clearly in people with head and neck cancer, either at diagnosis or if it comes back.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.